Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCHOLAR: Safety of Continued Trastuzumab with Cardiac Meds
NCT02907021Phase 1Completed
- Sponsor
- Population Health Research Institute
- Start
- Nov 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carvedilol and ramipril in heart failure (HF), sponsored by Population Health Research Institute. Primary endpoints: Safety outcomes (Cardiac Dose Limiting Toxicity) at 1 year and Efficacy outcomes at 1 year. Started Nov 2016; status: completed.
02
Drugs
carvedilolramipril
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02907021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907021.